ArticleJournal of thoracic disease2019

Who will suffer from hyperprogressive disease in patients with advanced non-small cell lung cancer treated with PD-1/PD-L1 inhibitors.

Motoko Tachihara et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.